One major hurdle in drug development is an incomplete understanding of the underlying mechanisms that drive A plaques and tau-containing neurofibrillary tangles (NFTs) in the brain which may begin decades prior to cognitive decline (9-11)
Furthermore, as previously mentioned, there is a lack of data on psychiatric adverse events associated with GLP-1 receptor agonists reported in clinical trials [13,14,15]
Safety Both treatment methods are safe, but theres a risk of side effects with each option
A campaign with a celebrity of Serena Williams' stature could be a turning point in the marketing of GLP-1 drugs, which have exploded in use since the U.S
Gasperi V et al
Unlike pharmaceutical GLP-1 agonists, which can cause gastrointestinal side effects such as nausea, vomiting, and diarrhoea, dietary approaches rarely produce significant adverse effects when implemented gradually